Filing Flows

Filing Flows › 8-K events › ANI Pharmaceuticals

ANI Pharmaceuticals: results of operations

Form 8-K filed Nov 5, 2026 · items 2.02, 7.01

FDA decisionsANI Pharmaceuticals Reports Third Quarter 2026 Financial Results

What the filing says

ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results • Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year

ScaleThe filing names $290.8M: about 25% of ANI Pharmaceuticals' annual revenue ($1.16B, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

ANI Pharmaceuticals at a glance

Latest quarterQ3 2026
Revenue$290.8M
Revenue Y/Y+28%
Operating margin18.0%
IndustryPharmaceutical Preparations

ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%. The chart follows the revenue to costs, profit and cash.

ANI Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

ANI Pharmaceuticals’s other material 8-Ks

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.